Targeting the NLRP3 inflammasome in Alzheimer’s disease: Mechanistic insights and therapeutic advances "It uncovers the inextricable role of NLRP3 inflammasome in AD pathogenesis from the preclinical and clinical evidence... It overviews the existing anti-AD agents that inhibit the NLRP3 inflammasome activation."

How do inflammasomes drive CAPS? A mass cytometry analysis decrypts how #NLRP3# mutations in patient neutrophils trigger the clustering of gasdermin D and E at the plasma membrane, leading to #pyroptosis# and the release of IL-1-beta. @UCSanDiego

How do inflammasomes drive CAPS? A mass cytometry analysis decrypts how #NLRP3# mutations in patient neutrophils trigger the clustering of gasdermin D and E at the plasma membrane, leading to #pyroptosis# and the release of IL-1-beta. @UCSanDiego

NOVO HOLDINGS-BACKED REZERA FILES FOR A NASDAQ IPO The clinical-stage company, which is developing oral NLRP3 inhibitors for cardiovascular and neurologic disease, plans to list under RZRA with Jefferies, TD Cowen and Cantor as joint bookrunners. Novo Holdings owned 24.42% and Blue Owl affiliates 24.03% before the IPO, per its SEC filing

Bloomberg News Now is a comprehensive audio report of today's top stories. Hear the latest news, updated throughout the day, covering global business stories in just a few minutes.